Intravenous Immunoglobulin Market Grow US$ 18,672.55 million by 2028
According to our latest study on “Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Application, Distribution Channel, End User, and Geography” the market is expected to grow from US$ 11,206.54 million in 2021 to US$ 18,672.55 million by 2028; it is expected to grow at a CAGR of 7.6% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment is likely to account for a larger market share during the forecast period. By application, the market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment held a larger market share in 2021 and is projected to continue its dominance during the forecast period. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others. By end user, the market is segmented into hospitals, specialty clinics, and others. The hospitals segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period.
Increasing Geriatric Population Drives Intravenous Immunoglobulin Market
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). As per the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 different types of primary immune deficiency diseases (PIDDs) affecting about 500,000 people in the US. The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the world annually.
Recommended by LinkedIn
As per the National Multiple Sclerosis Society study report published in 2019, around 1 million adults (about 913,925) were affected by multiple sclerosis (MS) in the US. According to the Multiple Sclerosis Society (MS Society UK), more than 130,000 people were suffering from MS in the UK in January 2020, and around 7,000 people are diagnosed with it every year. Additionally, as per the Department of Health, Australia, there are around 25,600 MS cases in Australia. IVIG is also used in the treatment of MS. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
The outbreak of COVID-19 pandemic had a positive impact on intravenous immunoglobulin market growth. according to a case study (2020) in Neuroimmunol Neuroinflammation Journal, intravenous immunoglobulin was successfully used to treat COVID-19-associated encephalitis of a patient in India. Additionally, various studies published in PubMed and NCBI by Chinese researchers also show that IVIg has demonstrated clinical efficacy in critically ill patients with COVID-19 in reducing the rate of mortality and increasing the length of hospitalization. Since the onset of the COVID-19 pandemic, there has been a disproportionate growth in the intravenous immunoglobulin market due to fewer hospital visits by patients. However, post-COVID, there has been a high demand for IVIg owing to its efficacy in the Covid-19 treatment and immunodeficiency-related health problems that contributes to the intravenous immunoglobulin market’s future growth.
Takeda Pharmaceutical Company Limited; Grifols, S.A.; Pfizer Inc.; ADMA Biologics Inc.; Bio Products Laboratory Ltd.; Shanghai RAAS; Octapharma AG; Kedrion S.p.A; CSL Behring (CSL Limited); and Prothya Biosolutions B.V. are among the leading companies operating in the global intravenous immunoglobulin market.